School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants
- A Greenough1,
- J Alexander2,
- P Boit2,
- J Boorman3,
- S Burgess4,
- A Burke5,
- P A Chetcuti4,
- I Cliff2,
- W Lenney2,
- T Lytle3,
- C Morgan5,
- C Raiman1,
- N J Shaw5,
- K P Sylvester1,
- J Turner6
- 1King’s College London, MRC-Asthma Centre, Division of Asthma, Allergy and Lung Biology, London, UK
- 2University Hospital of North Staffordshire, Stoke on Trent, UK
- 3Abbott Laboratories, Maidenhead, UK
- 4Leeds General Infirmary, Leeds, UK
- 5Liverpool Women’s Hospital, Liverpool, UK
- 6Premier Research Group, Crowthorne, UK
- Professor A Greenough, 4th Floor, Golden Jubilee Wing, King’s College Hospital, London SE5 8RS, UK; anne.greenough{at}kcl.ac.uk
- Received 8 January 2008
- Accepted 2 January 2009
- Published Online First 12 February 2009
Abstract
Background: Hospitalisation due to respiratory syncytial virus (RSV) infection in the first 2 years after birth has been associated with increased healthcare utilisation and associated costs up to 5 years of age in children born prematurely at less than 32 weeks of gestation who developed bronchopulmonary dysplasia (BPD). A study was undertaken to determine whether hospitalisation due to RSV infection in the first 2 years was associated with increased morbidity and lung function abnormalities in such children at school age, and if any effects were influenced by age.
Methods: Healthcare utilisation and cost of care in years 5–7 were reviewed in 147 children and changes in healthcare utilisation between 0 and 8 years were assessed also using results from two previous studies. At age 8–10 years, 77 children had their lung function assessed and bronchial hyper-responsiveness determined.
Results: Children hospitalised with RSV infection (n = 25) in the first 2 years had a greater cost of care related to outpatient attendance than those with a non-respiratory or no admission (n = 72) when aged 5–7 years (p = 0.008). At 8–10 years of age, children hospitalised with RSV infection (n = 14) had lower forced expiratory volume in 0.75 s (FEV0.75) (p = 0.015), FEV0.75/forced vital capacity (p = 0.027) and flows at 50% (p = 0.034) and 75% (p = 0.006) of vital capacity than children hospitalised for non-RSV causes (n = 63). Healthcare utilisation decreased with increasing age regardless of RSV hospitalisation status.
Conclusions: In prematurely born children who had BPD, hospitalisation due to RSV infection in the first 2 years is associated with reduced airway calibre at school age.
Footnotes
-
Competing interests: Abbott Laboratories market palivizumab, a monoclonal antibody for prophylaxis against RSV. AG, WL and PC have received honoraria for speaking at Abbott sponsored conferences. TL and JB are employees of Abbott Laboratories. TL was the clinical monitor and JB was the clinical project manager for this study.
-
Funding: The research nurses were funded by Abbott Laboratories Ltd and MedImmune.
-
Ethics approval: The study was approved by the local research ethics committees of the four hospitals.
-
‣ Additional appendix and figure are published online only at http://thorax.bmj.com/content/vol64/issue6
